Suppliers and packagers for FENSOLVI KIT

FENSOLVI KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150	NDA	TOLMAR Inc.	62935-153-50	1 KIT in 1 CARTON (62935-153-50) * .375 mL in 1 SYRINGE (62935-154-50) * .375 mL in 1 SYRINGE (62935-155-40)	2020-06-03
Tolmar	FENSOLVI KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	213150	NDA	TOLMAR Inc.	62935-163-60	1 SYRINGE in 1 CARTON (62935-163-60) / .375 mL in 1 SYRINGE	2023-03-06

Suppliers for the Pharmaceutical Drug: FENSOLVI KIT

Last updated: July 30, 2025

Introduction

FENSOLVI KIT (palonosetron hydrochloride injection) is a critical pharmaceutical in the management of chemotherapy-induced nausea and vomiting (CINV). As an antiemetic agent, it has been widely adopted in oncology settings. Securing reliable suppliers for FENSOLVI KIT is vital for healthcare providers, distributors, and pharmaceutical companies aiming to ensure continuous patient access, regulatory compliance, and effective inventory management. This article examines the origin, supply chain dynamics, key suppliers, and market considerations surrounding FENSOLVI KIT.

Overview of FENSOLVI KIT

FENSOLVI KIT, marketed by Helsinn Healthcare, contains palonosetron hydrochloride, a potent 5-HT3 receptor antagonist. Its unique pharmacological profile offers extended activity, making it a preferred choice among antiemetics for chemotherapy patients. The drug's formulation, requiring precise storage and handling, underscores the importance of qualified suppliers with established distribution channels.

Manufacturing and Supply Chain for FENSOLVI KIT

Helsinn Healthcare holds the patent and manufacturing rights for FENSOLVI KIT, with production facilities primarily located in Switzerland. The supply chain involves multiple stages:

1. Active Pharmaceutical Ingredient (API) Production: The core chemical entity, palonosetron, is synthesized centrally, often in specialized facilities with stringent regulatory standards.

2. Drug Formulation and Packaging: The API is processed into sterile injectable formulations, packaged into kits, and subjected to quality control inspections.

3. Distribution and Logistics: The finished kits are shipped globally through a network of authorized distributors, adhering to cold chain logistics to ensure drug stability.

Given these complexities, suppliers must adhere to international Good Manufacturing Practices (GMP) and hold relevant certifications.

Authorized Suppliers and Distribution Partners

Since FENSOLVI KIT is a proprietary product, Helsinn Healthcare curates its authorized distribution network. While specifics are often proprietary, a few key points can be made:

• Helsinn's Direct Distributors: Helsinn maintains strict control over its distribution channels. Authorized pharmaceutical wholesalers and distributors in major markets—such as the U.S., EU, and Asia—are directly appointed to distribute FENSOLVI KIT. These partners primarily include global pharmaceutical distribution giants and regional specialty pharmacies.

• Regional and Local Distributors: In various countries, regional distributors licensed by Helsinn or its regional partners handle procurement and distribution to healthcare facilities. These entities are vetted for compliance with local regulatory standards.

• Specialty Pharmacies and Hospital Suppliers: In some regions, hospital-based pharmacies and specialty drug providers hold direct agreements to supply FENSOLVI KIT to chemotherapy centers.

Notable distributors linked to Helsinn's global network include companies such as

• McKesson Corporation (U.S.)
• Fresenius Kabi (Europe and Asia)
• UMC Group (Asia)

However, exact supplier lists are often confidential and subject to change based on regional agreements and regulatory approvals.

Regulatory Considerations and Regional Approvals

Distribution and supply channels are heavily regulated. Helsinn's approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for FENSOLVI KIT requires that suppliers meet strict compliance standards, including GMP certifications, Good Distribution Practice (GDP), and traceability protocols.

For example, in the U.S., the Drug Supply Chain Security Act (DSCSA) emphasizes verified wholesale distributors, making transparency and traceability crucial. Similar regulations exist in the EU under the Falsified Medicines Directive (FMD).

Emerging Market Suppliers and Generic Alternatives

Currently, FENSOLVI KIT's patent exclusivity limits the availability of generics. However, as patent expiries approach in various jurisdictions, licensing agreements could enable local manufacturers to produce FENSOLVI or similar formulations.

In anticipation of increased competition, potential suppliers may include:

• Local generic manufacturers in emerging markets with technical capability to produce sterile injectable antiemetics.
• Contract Manufacturing Organizations (CMOs) that have existing GMP facilities and regulatory expertise.

Market Dynamics and Supply Challenges

Key considerations affecting supplier reliability include:

• Regulatory hurdles that delay approval or registration in new markets.
• Supply chain disruptions, especially in the context of global events such as pandemics.
• Manufacturing capacity constraints, exacerbated during periods of increased demand, e.g., during COVID-19 oncological care.

Helsinn actively manages these risks by maintaining strategic stockpiles and diversified distribution channels.

Conclusion

The supply landscape for FENSOLVI KIT is characterized by a tightly controlled network of authorized distributors, primarily managed by Helsinn Healthcare. As the patent and marketing exclusivity period progresses, additional suppliers may emerge, especially in the context of impending patent expirations and biosimilar developments. Ensuring supplier compliance with regional regulations and GMP standards remains critical for uninterrupted access to this essential antiemetic.

---

Key Takeaways

• Primary manufacturer: Helsinn Healthcare supplies FENSOLVI KIT, with distribution managed through authorized global distributors.
• Distribution channels: Include global pharma wholesalers, regional distributors, and specialty pharmacies, all adhering to GMP and GDP standards.
• Regulatory environment: Suppliers must meet regional regulatory requirements, with approvals from agencies like the FDA and EMA ensuring compliance.
• Market considerations: Patent exclusivity sustains supply control; patent expirations may open opportunities for generics.
• Supply chain resilience: Helsinn mitigates risks via diversified channels and inventory management, vital amid global disruptions.

---

FAQs

1. Who are the main suppliers of FENSOLVI KIT globally?
Helsinn Healthcare directly manages its distribution network with authorized pharmaceutical distributors such as McKesson, Fresenius Kabi, and regional partners. Exact supplier details vary by country and are often proprietary.

2. Can generic versions of palonosetron be considered substitutes for FENSOLVI KIT?
Currently, FENSOLVI KIT remains proprietary. Generic equivalents may become available post-patent expiry, but regulatory approval processes must be completed in each region.

3. What regulatory standards do suppliers of FENSOLVI KIT need to meet?
Suppliers must comply with GMP for manufacturing and GDP for distribution, ensuring drug safety, efficacy, and traceability in line with FDA, EMA, and regional standards.

4. How does supply chain disruption impact FENSOLVI KIT availability?
Global disruptions can cause delays or shortages. Helsinn mitigates this risk through strategic inventory management, multiple distribution partners, and contingency planning.

5. Are there regional differences in the supply of FENSOLVI KIT?
Yes. Regulatory approvals, distribution networks, and local licensing influence availability. Some regions rely on local distributors licensed by Helsinn, while others depend on regional hubs.

---

Sources:

1. Helsinn Healthcare. FENSOLVI (palonosetron hydrochloride injection) product monograph.
2. U.S. FDA Drug Approvals and Post-Market Reports [FDA.gov].
3. European Medicines Agency (EMA) approval database.
4. Industry reports on oncology drug distribution and supply chain management.
5. Pharmaceutical supply chain regulatory guidelines (WHO, ICH).